AL amyloidosis: The last 30 years

Amyloid

Volumn 7, Issue 1, 2000, Pages 13-14

  Skinner, Martha ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AL; Amyloid; Light chains

Indexed keywords

AMYLOID; AMYLOID LIGHT CHAIN; BENCE JONES PROTEIN; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMYLOIDOSIS; ARTICLE; AUTONOMIC NEUROPATHY; FAMILIAL DISEASE; HEPATOMEGALY; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA;

EID: 0034027762     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506120009146816     Document Type: Article

References (21)

1. Glenner GG, Harbaugh J, Ohms JI, Harada M and Cuatrecasas P (1970). An amyloid protein: the ammo-terminal variable fragment of an immunoglobulin light chain. Biochem Biophys Res Comm. 41, 1287-1289
2. Glenner GG, Terry W, Harada M, Isersky C and Page D (1971). Amyloid fibril proteins: Proof of homology with immunoglobulin light chains by sequence analysis. Science 172, 1150-1151
3. Osserman EF, Takatsuki K and Talal N (1964). The pathogenesis of "amyloidosis": studies on the role of abnormal gamma globulin fragments of the Bence-Jones type in the pathogenesis of "primary" and "secondary amyloidosis" and the "amyloidosis" associated with plasma cell myeloma. Semin Hematol 1, 1-85
4. Isobe T and Osserman EF (1974). Patterns of amyloidosis and their association with plasma cell dyscrasia, monoclonal immunoglobulins and Bence-Jones proteins. N Eng J Med 290, 473-477
5. Kyle RA and Bayrd ED (1975).Amyloidosis: review of 236 cases. Medicine 54,271-299
6. Kyle RA, Linos A and Beard (1992). Incidence and natural history of primary systemic amyloidosis in Olmstead County, Minnesota, 1950 through 1989. Blood 79,1817-1822
7. Kyle RA and Gertz MA (1995). Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 32, 45-59
8. Skinner M, Benson MD and Cohen AS (1975). Amyloid fibril protein related to immunoglobulin lambda-chains. J Immunol 114, 1433-1435
9. Sletten K, Natvig JB, Husby G and Juul J (1981). The complete amino acid sequence of a prototype immunoglobulin-lambda light-chain type amyloid fibril protein AR. Biochem J 195, 561-572
10. Solomon A, Frangione B and Franklin EC (1982). Bence Jones proteins and light chains of immunoglobulins. Preferential association of the Vlambda6 subgroup of human light chains and amyloidosis AL. J Clin Invest 70, 453-460
11. Ozaki S, Abe M, Wolfenbarger D, Weiss DT and Solomon A (1994). Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenstrom's macroglobulinemia. Clin Immunol Immunopath 71, 183-189
12. Perfetti V, Ubbiali P, Vignarelli MC, Diegoli M, Fasani R, Stoppini M, Lisa A, Mangione P, Obici L, Arbustini E and Merlini G (1998). Evidence that amyloidogenic light chains undergo antigen-driven selection. Blood 91, 2948-2954
13. Hurle MR, Helms LR, Li L, Chan W and Wetzel R (1994). A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci USA 91, 5446-5450
14. Myatt EA, Westholm FA, Weiss DT, Solomon A, Schiffer M and Stevens FJ (1994). Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition. Proc Natl Acad Sci 91, 3034-3038
15. Kyle RA and Greipp PR (1978). Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood 52, 818-827
16. Kyle RA, Greipp PR, Garton JP and Gertz MA (1985). Primary systemic amyloidosis: comparison of melphalan/prednisone versus colchicine. Am J Med 79, 708-716
17. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ and Therneau TM (1997). A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Eng J Med 336, 1202-1207
18. Benson MD (1986). Treatment of AL amyloidosis with melphalan, prednisone and colchicine. Arthritis Rheum 29, 683-687
19. Skinner M, Anderson JJ, Simms R, Falk R, Wang M, Libbey CA, Jones LA and Cohen AS (1996). Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 100, 290-298
20. Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller DV, Wright DG, Falk RH and Skinner M (1996). Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood, 88, 2801-2806
21. Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'Hara C, Arkin CF, Wright DG and Skinner M (1998). Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and response in 25 patients. Blood 91, 3662-3670.